Citations

Clear

20 citation(s) found for "Moore, Wendy".

DNA Sequencing Analysis of Cystic Fibrosis Transmembrane Regulator Gene Identifies Cystic Fibrosis-Associated Variants in the Severe Asthma Research Program.
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , L, Jennifer Taylor-Cousar, Cutting, Garry R. , Ampleford, Elizabeth J., Hawkins, Gregory A., Zein, Joe , Denlinger, Loren C. , Erzurum, Serpil C. , Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Woodruff, Prescott G. , Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Cutting, Gary R , Taylor‐Cousar, Jennifer L. , Castro, Mario , Fahy, John V. , Levy, Bruce David , Wenzel, Sally E.

Mayo Clinic

No container title available | April 19, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165037325.52611651/v1 Get It

Background: Heterozygote carriers of potentially pathogenic variants in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene have increased asthma risk. However, the frequency and impact of CFTR variation among individuals with asthma is unknown. Objective: To determine whether potentially pathogenic CFTR variants associate with disease severity and whether individuals with two potentially pathogenic variants exist in a severe asthma-enriched cohort . Methods : We analyzed sequencing data spanning a 190.5Kb region of CFTR in participants from the Severe Asthma Research Program (SARP1-3). Potentially pathogenic, rare CFTR variants (frequency<0.05) were classified as CF-causing or of varying clinical consequences (VVCC) (CFTR2.org). Regression-based models tested for association between CFTR genotypes (0-2 potentially pathogenic variants) and severity outcomes. Results: Of 1401 participants, 9.5% (134) had one potentially pathogenic variant, occurring more frequently in non-Hispanic white (NHW, 10.1% [84 of 831]) compared to African American individuals (AA, 5.2% [22 of 426]). We found ≥2 potentially pathogenic CFTR variants in 1.4% (19); 0.5% (4) of NHW and 2.8% (12) of AA. Potentially pathogenic CFTR variant genotypes (≥1 or ≥2 variants) were not cumulatively associated with lung function or exacerbations. In NHW, we found three F508del compound heterozygotes with F508del and a VVCC (two 5T;TG12[c.1210-11T>G] and one Arg1070Trp) and a homozygote for the VVCC, 5T;TG12. Conclusions: We found potentially pathogenic CFTR variants within a severe asthma-enriched cohort , including three compound heterozygote genotypes variably associated with CF in NHW individuals. These findings provide the rationale for CFTR sequencing and phenotyping of CF-related traits in individuals with severe asthma.
Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
Smart, Dave, Moore, Wendy C. , Hjort, Karina, Keating, Karen , Holt, Bob, Henderson, Raymond , Riccelli, Peter V., Magliocco, Anthony M., Hanson, Curtis A. , Moore, Wendy, Bloom, Kenneth

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 5017-5017

10.1182/blood-2021-153005 Get It

Abstract Introduction Measures taken to mitigate infection spread during the 2020 COVID-19 pandemic are considered to have caused significant unintended consequences on other diseases. Large decreases in the numbers of symptomatic and asymptomatic people presenting for diagnosis of heart disease, diabetes and cancer have been observed. A recent analysis of solid tumors showed up to 70% reduction in the number of patients presenting for diagnosis. The potential exists for significantly increased morbidity and mortality for these missed or delayed presenting patients. Further, it is important to determine whether infection spread mitigation measures affected the diagnostic testing and treatment decisions for these patients. This study aimed to determine whether pandemic control measures affected presentation, testing and treatment of patients across eight different hematologic cancers. Methods CMS claims data were analyzed for the presence of diagnostic (DX) ICD 10 codes indicative of hematologic cancer. Patients with a DX code first appearing in 2019 or in 2020 were selected to provide newly diagnosed pre-COVID-19 and during COVID-19 cohorts for comparison, with unique patient counts being calculated for each month. A "COVID-19 dip" i.e. a decrease in the number of patients was calculated as the change in number of patients diagnosed in a given month relative to the number for JAN2020. Dip duration was calculated only when the decrease was &gt;10% of the JAN2020 figure. Patients who received treatment via a "J" code Healthcare Common Procedure Coding System (HCPCS) code were extracted from the cohorts and the time taken from initial diagnosis to first treatment calculated. Results Eight hematologic cancers: AML, CLL, CML, HEME (a group of different hematologic cancers), Hodgkins (HOG), Myelodysplasia (MDS), Non-Follicular Lymphomas (NFL), and Non-Hodgkins Lymphoma (NHL) showed a decrease in the number of patients being diagnosed during the early part of 2020 (Fig.1) Fig.1. Change in new patient diagnoses for selected hematologic cancers as a proportion of their JAN2020 value There was some variation in the depth and duration of the COVID-19 dip (Table 1) with MDS having both the longest and deepest dip. Median depth and duration of the dip was 33% and 3.5 months, respectively, with all dips starting either in FEB or MAR2020. Table 1. Duration and depth of COVID-19 dips for selected hematological cancers The proportions of patients receiving therapy via J HCPCS code (JRX) are shown in Table 2 Table 2. Proportions of patients receiving J code therapy Conclusions The decline in new patient diagnoses for heme cancers during the period when COVID-19 control measures were implemented is similar to that seen with solid tumors, although the depth of the COVID-19 dip was generally larger in the latter. There is no evidence of "catch up" diagnosis occurring i.e. patients missing from Q2 2020 are not reappearing en masse in subsequent quarters. The decline for MDS patients has, except for SEP to OCT2020, remained. Collectively, (depending on the calculation method), the COVID-19 dip for these eight heme cancers represents 16,584-33,671 patients who will likely have significantly increased rates of morbidity and mortality due to delayed diagnosis. Analysis of J code treatments show little difference between the proportions of patients receiving these treatments in 2020 compared to 2019 suggesting that at least some aspects of treatment e.g. infused chemotherapy, IO drugs for these patients was relatively unchanged by pandemic control measures. It also suggests that the main cause for decreased patient numbers treated is due to decreased testing for diagnosis, rather than not being treated once diagnosed. This aligns with findings from studies in the US and UK. The results of this study indicate that there may be a "backlog" of tens of thousands of people with cancer whose diagnosis has been significantly delayed and who urgently need to be identified in order to get on proper treatment to lessen the impact of that delay. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
0895 Pediatric Positive Pressure Therapy: Enhancing Education And Parent/guardian Confidence To Implement Therapy
Moore, Wendy , Anderson, Stephen E. , Burr, L E, Clark, Peter, Peine, N A, Sydejko, D M, Wahl, Alexander, Hale, Andrea, Baughn, Julie , Anderson, S E, Wahl, A M

Mayo Clinic

Sleep | May 27, 2020 | Volume: 43 | Issue: Supplement_1 | Pages: A341-A341

10.1093/sleep/zsaa056.891 Get It

Abstract Introduction Pediatric positive airway pressure (PAP) therapy can be challenging for children and their parent/guardian (PG). These challenges are complicated by the need to facilitate behavioral competency in the management of both device equipment and therapy. Methods As part of a larger quality management project aimed to improve PG and patient satisfaction we developed a targeted education visit provided by registered nurses prior to PAP trial initiation. Principle aims were to measure satisfaction with education and increase PG confidence in ability to manage therapy. The nurse session included: education on Obstructive Sleep Apnea (OSA) and PAP therapy, development of plan for first month of therapy, concepts of desensitization, regular practice, discussion and identification of concerns (assessment of barriers to implementation). A survey was administered pre-intervention to assess PG confidence in ability to manage therapy. Post-intervention, PG rated the interventions impact on baseline confidence, as well as an assessment of satisfaction with the education and content. Descriptive statistics were utilized to summarize the Likert survey questions. Results A total of 21of 25 (84%) participants completed surveys. 100% of PG that responded was either extremely satisfied or very satisfied with the educational intervention. Prior to the intervention, 19% (N4) indicated little to no confidence, 19% (N4) indicated some confidence and 62% (N13) indicated being very confident. 62% (N13) of PG’s indicated the information covered was new to them, while 24% (N5) indicated some information was new and 14% (N3) indicated none of the information was new. Regardless of baseline confidence, 100% (N21) responded that the intervention further improved confidence to a great degree. Conclusion The nurse visit resulted in high satisfaction with care and education and impacted PG confidence in ability to implement treatment. Future studies are needed to determine the impact on patient compliance. Support
Enhancing the patient and family experience during pediatric sleep studies
Baughn, Julie , Lechner, Hannah G., Herold, Daniel L. , Brown, Virginia , Moore, Wendy , Harris, Cameron, Stehr, Heidi I., Sorensen, Channing, Cleveland, Eric J., Akason, James D., Lloyd, Robin M. , Baughn, Julie M, Brown, Virginia A, Moore, Wendy R, Harris, Cameron D, Sorensen, Channing M, Morgenthaler, Timothy I.

Mayo Clinic

Journal of Clinical Sleep Medicine | February 17, 2020 | Volume: 16 | Issue: 7 | Pages: 1037-1043

10.5664/jcsm.8386 | PMID 32065112 Get It

0966 Navigating the Path to Primary Care Involvement in the Care of Stable Obstructive Sleep Apnea Patients
Moore, Wendy , Harris, Cameron, Kakkar, Gurnoor S, Herold, Daniel L. , Williams, Julie A., Cleveland, Eric J., Mansukhani, Meghna P. , Morgenthaler, Timothy I.

Mayo Clinic

Sleep | April 13, 2019 | Volume: 42 | Issue: Supplement_1 | Pages: A388-A389

10.1093/sleep/zsz067.963 Get It

Team Approach: Management of Scapholunate Instability
Kamal, Robin N. , Moore, Wendy C. , Kakar, Sanjeev , Moore, Wendy , Kakar, Sanjeev , Kamal, Robin N

Mayo Clinic

JBJS Reviews | February 5, 2019 | Volume: 7 | Issue: 2 | Pages: e2-e2

10.2106/jbjs.rvw.18.00021 | PMID 30724763 Get It

* The wrist maintains stability through complex articulations of the carpal bones, dependent upon intrinsic and extrinsic ligaments. * Injury to the scapholunate interosseous ligament may lead to dissociative carpal instability, abnormal carpal kinetics, and sometimes arthritis. * The kinematics, kinetics, and self-stabilizing role of the tendons and their influence on the scapholunate interosseous ligament continue to be studied. * Critical to successful treatment of scapholunate interosseous ligament injuries is timely and complementary therapy. * There is currently no gold standard for a treatment algorithm for this condition.
1080 The Collaborative Care Visit Model: A New Way to Provide Ongoing Care Targeted to Long-Term Stable Positive Airway Pressure Users
Moore, Wendy , Burr, L E, McNamara, Sara, Clark, Peter, Peine, N A, Finstuen, Thomas, Herold, Daniel L., Brown, Vicki, Warner, Christopher H. , Trapp, Gerald, Olson, Eric J. , Auger, R. Robert , Louis, Erik K. St. , Junna, Mithri R. , St Louis, E K , Herold, Daniel L. , Lipford, Melissa C.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A401-A401

10.1093/sleep/zsy061.1079 Get It

1056 Exploring the Impact of a Sleep Enhancement Program in the Inpatient Environment on Patient Satisfaction: Lessons Learned
Moore, Wendy , Stellpflug, C, Ashbeck, R, Cutshall, S, Klevin, K, Marsh, Shona, Olson, Eric J. , Stellpflug, Courtney, Ashbeck, Rebecca, Marsh, S, Morgenthaler, Timothy I. , Lim, Kaiser G.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A393-A393

10.1093/sleep/zsy061.1055 Get It

Characterizing the Emotions That Trigger Cataplexy
Krahn, Lois E., Lymp, James, Moore, Wendy , Slocumb, Nancy L., Silber, Michael H.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | December 17, 2014 | Volume: 17 | Issue: 1 | Pages: 45-50

10.1176/jnp.17.1.45 | PMID 15746482 Get It

The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis
Furuta, Glenn T. , Kagalwalla, Amir F. , Lee, James J. , Alumkal, Preeth, Maybruck, Brian T., Fillon, Sophie, Masterson, Joanne C. , Ochkur, Sergei I. , Protheroe, Cheryl, Moore, Wendy , Pan, Zhaoxing , Amsden, Katie, Robinson, Z. D. , Mukkada, Vincent A. , Atkins, Dan, Fleischer, David M., Hosford, Lindsay , Kwatia, Mark A., Schroeder, Shauna , Kelly, Caleb , Lovell, Mark A. , Melín‐Aldana, Héctor, Ackerman, Steven J. , Capocelli, Kelley E.

Mayo Clinic

Gut | August 15, 2012 | Volume: 62 | Issue: 10 | Pages: 1395-1405

10.1136/gutjnl-2012-303171 | PMID 22895393 Get It

Objective Eosinophil predominant inflammation characterises histological features of eosinophilic oesophagitis (EoE). Endoscopy with biopsy is currently the only method to assess oesophageal mucosal inflammation in EoE. We hypothesised that measurements of luminal eosinophil-derived proteins would correlate with oesophageal mucosal inflammation in children with EoE. Design The Enterotest diagnostic device was used to develop an oesophageal string test (EST) as a minimally invasive clinical device. EST samples and oesophageal mucosal biopsies were obtained from children undergoing upper endoscopy for clinically defined indications. Eosinophil-derived proteins including eosinophil secondary granule proteins (major basic protein-1, eosinophil-derived neurotoxin, eosinophil cationic protein, eosinophil peroxidase) and Charcot–Leyden crystal protein/galectin-10 were measured by ELISA in luminal effluents eluted from ESTs and extracts of mucosal biopsies. Results ESTs were performed in 41 children with active EoE (n=14), EoE in remission (n=8), gastro-oesophageal reflux disease (n=4) and controls with normal oesophagus (n=15). EST measurement of eosinophil-derived protein biomarkers significantly distinguished between children with active EoE, treated EoE in remission, gastro-oesophageal reflux disease and normal oesophagus. Levels of luminal eosinophil-derived proteins in EST samples significantly correlated with peak and mean oesophageal eosinophils/high power field (HPF), eosinophil peroxidase indices and levels of the same eosinophil-derived proteins in extracts of oesophageal biopsies. Conclusions The presence of eosinophil-derived proteins in luminal secretions is reflective of mucosal inflammation in children with EoE. The EST is a novel, minimally invasive device for measuring oesophageal eosinophilic inflammation in children with EoE.